Efficacy of NK Cell Immunotherapy for Cancer (Osaki Method): An Outcomes Review
Background / Problem
Natural Killer (NK) cells are frontline immune cells that patrol the bloodstream to eliminate virus-infected and cancerous cells. In healthy people they make up roughly 5–10% of all white blood cells, and studies report that people with higher NK cell activity tend to have lower cancer incidence.
The key to therapy is NK cell function, not just count. Cells reinfused into the body must be in a functionally ready state, which depends heavily on the laboratory expansion method used.
Expansion Technology (Osaki Method)
NK cells can be expanded using feeder-cell-based or feeder-free methods. MEDEZE uses the feeder-free Osaki Method, developed by Dr. Junichi Masuyama of the New City Osaki Clinic in Japan, culturing cells in a proprietary medium within a patented closed system so that the NK cells are activated and immediately ready to work upon reinfusion.
- 1Collect blood samples and isolate the patient's NK cells
- 2Expand and activate them via the Osaki Method in a closed system
- 3Verify yield and functional readiness before reinfusion
- 4Reinfuse alongside primary treatment and follow up
Reported Outcomes
NK cells expanded using the Osaki Method have been reported to increase activated NK cell numbers by approximately 510–1,500-fold. In Japan, Osaki-Method NK cells are used alongside standard treatment for pancreatic, colorectal, lung, and gastric cancer, and a reported case in Thailand involved a late-stage lung cancer patient unresponsive to chemotherapy whose condition improved progressively after treatment.
- The Osaki Method increases activated NK cell numbers by about 510–1,500-fold
- Used in Japan alongside standard care for pancreatic, colorectal, lung, and gastric cancer
- A reported Thai case of late-stage lung cancer improved after treatment
Key Findings / Insights
- The feeder-free Osaki Method aims to preserve NK cell functional readiness after reinfusion
- NK cell immune support is a complementary approach used alongside standard cancer treatment
- Outcomes depend on cancer type and stage and should be assessed individually
References
- Imai K, et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. The Lancet. 2000;356(9244):1795-1799.
- Masuyama J, et al. NK cell therapy for end-stage cancerous patient: a case study. South Asian Journal of Cancer. 2014;3(2):143.
- Masuyama J, et al. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies. Cytotherapy. 2016;18(1):80-90.
- Wu SY, et al. Natural killer cells in cancer biology and therapy. Molecular Cancer. 2020;19(1):120.
- New City Osaki Clinic. Types of cancer and number of cases treated. 2021. https://www.nco-clinic.jp/e/case/index.html
Related Resources
Frequently Asked Questions (FAQs)
Can NK cell support replace standard cancer treatment?
NK cell immune support is complementary, not a replacement for primary treatments such as surgery, chemotherapy, or radiation, and should be undertaken under medical supervision.